Clinical Trial Update: One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study [EARLY_Phase 1]

View source ↗

Summary

A one-week intravenous dose-escalation Phase 1 study of parathyroid hormone-related protein (PTHrP) completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Humoral Hypercalcemia of Malignancy
• Hyperparathyroidism
• Osteoporosis

Drugs mentioned

• PTHrP IV (parathyroid hormone-related protein)

Snippet

Sponsor: University of Pittsburgh | Conditions: Osteoporosis, Humoral Hypercalcemia of Malignancy | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2016-02-11